1. Home
  2. OCUL vs UNIT Comparison

OCUL vs UNIT Comparison

Compare OCUL & UNIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCUL
  • UNIT
  • Stock Information
  • Founded
  • OCUL 2006
  • UNIT 2015
  • Country
  • OCUL United States
  • UNIT United States
  • Employees
  • OCUL N/A
  • UNIT N/A
  • Industry
  • OCUL Biotechnology: Pharmaceutical Preparations
  • UNIT Real Estate Investment Trusts
  • Sector
  • OCUL Health Care
  • UNIT Real Estate
  • Exchange
  • OCUL Nasdaq
  • UNIT Nasdaq
  • Market Cap
  • OCUL 1.2B
  • UNIT 1.3B
  • IPO Year
  • OCUL 2014
  • UNIT N/A
  • Fundamental
  • Price
  • OCUL $7.00
  • UNIT $5.62
  • Analyst Decision
  • OCUL Strong Buy
  • UNIT Buy
  • Analyst Count
  • OCUL 7
  • UNIT 3
  • Target Price
  • OCUL $16.71
  • UNIT $7.33
  • AVG Volume (30 Days)
  • OCUL 917.6K
  • UNIT 1.9M
  • Earning Date
  • OCUL 03-10-2025
  • UNIT 02-21-2025
  • Dividend Yield
  • OCUL N/A
  • UNIT 5.30%
  • EPS Growth
  • OCUL N/A
  • UNIT N/A
  • EPS
  • OCUL N/A
  • UNIT 0.38
  • Revenue
  • OCUL $61,442,000.00
  • UNIT $1,166,927,000.00
  • Revenue This Year
  • OCUL $11.40
  • UNIT N/A
  • Revenue Next Year
  • OCUL $13.58
  • UNIT $3.94
  • P/E Ratio
  • OCUL N/A
  • UNIT $14.26
  • Revenue Growth
  • OCUL 6.45
  • UNIT 1.49
  • 52 Week Low
  • OCUL $4.06
  • UNIT $2.57
  • 52 Week High
  • OCUL $11.78
  • UNIT $6.71
  • Technical
  • Relative Strength Index (RSI)
  • OCUL 31.92
  • UNIT 52.52
  • Support Level
  • OCUL $7.14
  • UNIT $5.33
  • Resistance Level
  • OCUL $7.42
  • UNIT $5.86
  • Average True Range (ATR)
  • OCUL 0.37
  • UNIT 0.22
  • MACD
  • OCUL -0.02
  • UNIT 0.01
  • Stochastic Oscillator
  • OCUL 0.76
  • UNIT 60.87

About OCUL Ocular Therapeutix Inc.

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

About UNIT Uniti Group Inc.

Uniti is a REIT with about 140,000 route miles of fiber in the us, primarily in the Southeast. It has agreed to merge with Windstream, which will result in Uniti giving up its REIT status and adding a consumer telecom business line. Uniti's business currently consists exclusively of fiber leasing to enterprises. Windstream currently leases the Uniti network and makes up the bulk of Uniti's revenue and profits. The combined firm will own 217,000 route miles of fiber and pass 4.3 million households and 150,000 commercial buildings, mostly in less populated markets in the Southeast. The firm will continue to offer fiber access to enterprises, as Uniti currently does, but residential telecom services will become its largest revenue stream.

Share on Social Networks: